Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 45, Issue 5 (May 2007)

Issues

Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumours

Miriam Lenhard
  • 1Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University, Munich, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Caroline Kuemper
  • 2Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University, Munich, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Nina Ditsch
  • 3Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University, Munich, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Joachim Diebold / Petra Stieber / Klaus Friese
  • 6Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University, Munich, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Alexander Burges
  • 7Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University, Munich, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2007-05-07 | DOI: https://doi.org/10.1515/CCLM.2007.120

Abstract

Background: Sertoli-Leydig cell tumours of the ovary account for only 0.2% of malignant ovarian tumours. Two-thirds of all patients become apparent due to the tumour's hormone production.

Methods: A 41-year-old patient (gravida 4, para 4) presented with dyspnoea, enlarged abdominal girth and melaena. Diagnostic imaging was suspicious for an ovarian cancer. The standard tumour marker for ovarian cancer (CA 125) was elevated to 984 U/mL.

Results: Surgical exploration of the abdomen revealed a mouldering tumour of both adnexes extending to the level of the navel. Frozen sections showed an undifferentiated carcinoma of unknown origin. Radical surgery was performed. The final histological report described a malignant sex-cord stroma tumour, a Sertoli-Leydig cell tumour, emanating from both ovaries. Analysis of preoperative blood serum showed elevated levels of CYFRA 21-1 (10.4 ng/mL), neuron-specific enolase (36.2 ng/mL), oestradiol (485 pg/mL) and CA-125 (984 U/mL). Adjuvant chemotherapy and regional hyperthermia were performed due to the malignant potential and incomplete resection of the tumour.

Conclusions: Undifferentiated Sertoli-Leydig cell tumours show a poor clinical course. As only two-thirds of patients with this rare disease present with elevated hormone levels, new markers deserve further investigation to offer more specific, individualised tumour monitoring.

Clin Chem Lab Med 2007;45:657–61.

Keywords: ovarian malignancy; Sertoli-Leydig cell tumour; serum marker; sex-cord stromal tumour

About the article

Corresponding author: Miriam Lenhard, MD, Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University Munich, Campus Grosshadern, Marchioninistrasse 15, 80337 Munich, Germany Phone: +49-89-7095-0, Fax: +49-89-7095-5844,


Received: 2006-12-19

Accepted: 2007-02-20

Published Online: 2007-05-07

Published in Print: 2007-05-01


Citation Information: Clinical Chemical Laboratory Medicine, ISSN (Online) 14346621, ISSN (Print) 14374331, DOI: https://doi.org/10.1515/CCLM.2007.120.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Rachel Brightwell, Kassondra Grzankowski, John Kasznica, and Peter J. Frederick
Gynecologic Oncology Reports, 2015, Volume 14, Page 6
[2]
Hong Shu, Xiang hong Yang, and Ai Feng Gao
Fetal and Pediatric Pathology, 2012, Volume 31, Number 6, Page 388
[3]
Ranju Ralhan, Olena Masui, Leroi V. DeSouza, Ajay Matta, Muzafar Macha, and K. W. Michael Siu
PROTEOMICS, 2011, Volume 11, Number 12, Page 2363
[4]
Celestine S Tung, Kwong-Kwok Wong, and Samuel C Mok
Women's Health, 2008, Volume 4, Number 1, Page 27

Comments (0)

Please log in or register to comment.
Log in